Entropy Neurodynamics Limited (ASX:ENP)

Market Cap	54.97M +16.4%
Revenue (ttm)	1.58M +19.2%
Net Income	-4.74M
EPS	-0.00
Shares Out	1.62B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,223,026
Average Volume	2,082,597
Open	0.0330
Previous Close	0.0330
Day's Range	0.0320 - 0.0340
52-Week Range	0.0270 - 0.0460
Beta	n/a
RSI	43.81
Earnings Date	May 29, 2026

About Entropy Neurodynamics

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ENP

Financial Performance

In fiscal year 2025, Entropy Neurodynamics's revenue was 1.58 million, an increase of 19.17% compared to the previous year's 1.33 million. Losses were -5.33 million, -27.66% less than in 2024.